Delcath Systems to Participate at Upcoming Virtual Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Delcath Systems (DCTH) announced its participation in two upcoming virtual investor conferences. The HC Wainwright Global Life Sciences Conference will occur on March 9, 2021, with on-demand viewing starting at 7:00 AM (ET). A webcast link is available for attendees. Additionally, Delcath will attend the 33rd Annual Roth Conference, scheduled for March 15-17, 2021, allowing for 1x1 meetings only. Delcath focuses on oncology treatments for liver cancers, with its investigational product, HEPZATO KIT, targeting high-dose chemotherapy treatment.
Details
News Market Reaction – DCTH
The recorded move for DCTH in the trading session of this news was -1.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences:
- HC Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021. On demand viewing begins at 7:00 am (ET)
- Virtual 33rd Annual Roth Conference March 15 – 17
- 1x1 meetings only
For more information or to schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.